Results 191 to 200 of about 81,528 (247)

Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence

Journal of Allergy and Clinical Immunology, 2017
M. Maurer, M. Metz, R. Brehler, U. Hillen, T. Jakob, V. Mahler, C. Pföhler, P. Staubach, R. Treudler, B. Wedi, M. Magerl   +10 more
semanticscholar   +1 more source

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.

JAMA Dermatol
Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M.   +12 more
europepmc   +1 more source

Dupilumab in patients with cold urticaria: Results from a phase 3 trial. [PDF]

J Allergy Clin Immunol Glob
Metz M, Saini SS, Yagami A, Gagnon R, Giménez-Arnau AM, Luo X, Robinson LB, Martinčová R, Radin A, Makhija M.   +9 more
europepmc   +1 more source

Casein as rare elicitor of food allergy dependent on augmentation factors ‐ A case report

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Charlotte Jasmin Kiani, Valentina Faihs, Julia Felicitas Pilz, Claudia Kugler, Tilo Biedermann, Knut Brockow   +5 more
wiley   +1 more source

Full‐Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open‐Label Study

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The aim of this Phase I/II open‐label study was to assess the safety and efficacy of NTI164, a novel full‐spectrum medicinal cannabis plant extract 0.08% Δ‐9‐tetrahydrocannabinol (THC), in Rett syndrome (RTT). Methods Eleven female participants (5–16 years) with a pathogenic variant in the MECP2 gene were recruited to this study, receiving
B. A. Keating, Y. Ogru, T. G. Duthy, L. Douglas, K. Lichkus, E. Isikgel, M. C. Fahey, C. Ellaway   +7 more
wiley   +1 more source

Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review

Pediatric Dermatology, EarlyView.
ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang, Aliyah King, Adam Byrne, Carmen Liy‐Wong   +3 more
wiley   +1 more source

Rapid Clinical Response to Omalizumab Treatment in Pediatric Acute Urticaria Associated with Mycoplasma Infection: A Two-Case Report. [PDF]

Pediatr Rep
Wu ZL, Huang YS, Chiang CT, Yu HR.
europepmc   +1 more source

The Inpatient Burden of Pediatric Dermatology in the United States: A National Analysis of the 2022 Kids' Inpatient Database

Pediatric Dermatology, EarlyView.
ABSTRACT Background Dermatologic conditions are a significant reason for pediatric hospitalizations in the United States. A prior analysis of the 2012 Kids' Inpatient Database (KID) established a national benchmark for this burden, but changes in medical coding, healthcare delivery, and demographics necessitate an updated assessment.
Shiv Patel, Aayush Shah, Vibhusha Kolli, Peter A. Lio   +3 more
wiley   +1 more source